Hexis Lab is a technology company working at the forefront of raw material innovation. Hexis Lab produce ground-breaking ethnically targeted skincare products to protect and repair sun-damaged skin and improve life well-being. The company's discovery platform utilizes big data cloud computing approaches and in-silico computer modelling to screen a huge database of natural plant derived compounds for activity against our selected cellular targets.
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials.
aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling it to provide breakthrough therapeutics to addiction sufferers in desperate need.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
CONNECT Care gives patients the confidence to manage their medications.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
PheroSyn specializes in the development and production of innovative pest pheromones aimed at enhancing agricultural practices. A spin-out from Rothamsted Research, a prominent non-profit research center, PheroSyn focuses on creating pheromone-based integrated pesticides. These products utilize pheromone traps to effectively attract specific pest species, allowing farmers to monitor pest infestations accurately. By providing clear indicators of pest presence, PheroSyn's solutions help farmers minimize unnecessary over-spraying, thereby improving cost efficiency and optimizing resource utilization. The company's approach contributes to more sustainable agricultural practices, benefiting farmers and society as a whole.
Xampla Ltd develops and produces a pea plant protein-based plastic material to replace microplastics for commercial use. The company’s products include microcapsules for application in homecare and personal care products; and films, coatings, and single use plastics for application in single and multi-layer films, coatings, and packaging products. Xampla Ltd was incorporated in 2018 and is based in Cambridge, United Kingdom.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
Vamstar operates a B2B healthcare supply chain platform that aims to streamline sourcing and procurement for medical device and pharmaceutical companies. The platform utilizes advanced technologies such as machine learning and data automation to aggregate demand from millions of sources, providing real-time analytics to facilitate transactions between buyers, such as hospitals and health systems, and suppliers, including manufacturers and service providers. By capturing over £1.5 trillion of global demand, Vamstar enables healthcare companies to quickly identify suitable opportunities and finalize deals more efficiently. The platform features millions of contracts from various countries, allowing suppliers to bid on opportunities. Vamstar has partnered with some of the most innovative healthcare companies and continues to develop its digital marketplace, backed by notable investors and recognized for its innovation within the industry.
CONNECT Care gives patients the confidence to manage their medications.
PheroSyn specializes in the development and production of innovative pest pheromones aimed at enhancing agricultural practices. A spin-out from Rothamsted Research, a prominent non-profit research center, PheroSyn focuses on creating pheromone-based integrated pesticides. These products utilize pheromone traps to effectively attract specific pest species, allowing farmers to monitor pest infestations accurately. By providing clear indicators of pest presence, PheroSyn's solutions help farmers minimize unnecessary over-spraying, thereby improving cost efficiency and optimizing resource utilization. The company's approach contributes to more sustainable agricultural practices, benefiting farmers and society as a whole.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Camallergy Limited, founded in 2015 and based in Cambridge, United Kingdom, specializes in the development and manufacture of oral immunotherapy drugs targeting food allergies, particularly peanut allergies. The company's innovative treatments aim to provide a patient-centric solution that offers rapid protection, allowing individuals to manage their allergies effectively within a few weeks of therapy. By focusing on the needs of those affected by food allergies, Camallergy seeks to enhance the quality of life for patients, enabling them to live without the constant fear associated with allergic reactions.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Vamstar operates a B2B healthcare supply chain platform that aims to streamline sourcing and procurement for medical device and pharmaceutical companies. The platform utilizes advanced technologies such as machine learning and data automation to aggregate demand from millions of sources, providing real-time analytics to facilitate transactions between buyers, such as hospitals and health systems, and suppliers, including manufacturers and service providers. By capturing over £1.5 trillion of global demand, Vamstar enables healthcare companies to quickly identify suitable opportunities and finalize deals more efficiently. The platform features millions of contracts from various countries, allowing suppliers to bid on opportunities. Vamstar has partnered with some of the most innovative healthcare companies and continues to develop its digital marketplace, backed by notable investors and recognized for its innovation within the industry.
Datalase Ltd. specializes in developing materials for laser coding and marking across various industries, including pharmaceuticals, food and beverage, electronics, cosmetics, and tobacco. The company's innovative ink solutions enable high-speed, in-line digital printing, allowing for the customization of packaging with variable information such as date and lot codes, barcodes, and graphics. Datalase's proprietary technology is designed for use on outercases, products, and primary packaging, enhancing quality and operational efficiency for brand owners. The company operates through a partner network in Europe, the United States, and Asia, and has established strategic partnerships with key industry players. Founded in 1987 and based in Widnes, United Kingdom, Datalase was previously known as Sherwood Technology Ltd. before rebranding in 2006.
Aramune Technologies is developing natural, plant derived feed materials which can be mixed with standard animal feeds to replace antimicrobial agents and promote growth.
Vamstar operates a B2B healthcare supply chain platform that aims to streamline sourcing and procurement for medical device and pharmaceutical companies. The platform utilizes advanced technologies such as machine learning and data automation to aggregate demand from millions of sources, providing real-time analytics to facilitate transactions between buyers, such as hospitals and health systems, and suppliers, including manufacturers and service providers. By capturing over £1.5 trillion of global demand, Vamstar enables healthcare companies to quickly identify suitable opportunities and finalize deals more efficiently. The platform features millions of contracts from various countries, allowing suppliers to bid on opportunities. Vamstar has partnered with some of the most innovative healthcare companies and continues to develop its digital marketplace, backed by notable investors and recognized for its innovation within the industry.
4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.
Mimica Lab Ltd., established in 2017 and based in London, develops innovative freshness indicators for perishable products, including food and pharmaceuticals. The company's flagship product, Mimica Touch, features a patented label or cap that becomes bumpy to signal when a product is no longer safe for consumption, based on real-time temperature conditions. This tactile interface provides a clear indication of freshness calibrated to various food types, addressing the critical issue of food waste, which affects a significant portion of global food production. Research suggests that utilizing Mimica Touch could lead to a 50% reduction in retail food waste and a 60% decrease in waste at home. By improving food safety and efficiency, Mimica aims to prevent millions of tonnes of food from being discarded, thereby contributing to a more sustainable food system.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Vamstar operates a B2B healthcare supply chain platform that aims to streamline sourcing and procurement for medical device and pharmaceutical companies. The platform utilizes advanced technologies such as machine learning and data automation to aggregate demand from millions of sources, providing real-time analytics to facilitate transactions between buyers, such as hospitals and health systems, and suppliers, including manufacturers and service providers. By capturing over £1.5 trillion of global demand, Vamstar enables healthcare companies to quickly identify suitable opportunities and finalize deals more efficiently. The platform features millions of contracts from various countries, allowing suppliers to bid on opportunities. Vamstar has partnered with some of the most innovative healthcare companies and continues to develop its digital marketplace, backed by notable investors and recognized for its innovation within the industry.
Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Lunac Therapeutics
Grant in 2019
Lunac Therapeutics is a UK-based drug discovery company.
high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
SageTech Medical Equipment specializes in the development of anesthetic technology for both human and veterinary healthcare providers. Founded in 2015 and based in Paignton, United Kingdom, the company has created a patented process that captures, extracts, and purifies inhalational anesthetic agents. This innovative approach not only offers significant cost savings but also addresses environmental concerns associated with anesthetic waste. SageTech's systems are designed to operate on both industrial and compact scales, allowing for bulk capture in larger settings as well as integration into anesthetic machines for recycling in clinical environments. By promoting a circular economy for anesthetic agents, SageTech provides a sustainable solution that benefits healthcare providers and the environment alike.
Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton in collaboration with the University of Warwick, Medherant aims to address the limitations of existing patch technologies, which often struggle with drug loading capabilities and are unsuitable for many pharmaceutical products. The company's flagship product, the TEPI Patch, utilizes a novel adhesive that enhances drug delivery by allowing for higher concentrations and faster release rates, while mitigating the issues associated with oral medications, such as gastrointestinal toxicity and low bioavailability.
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company’s lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston, US. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Phico Therapeutics Limited operates as a biotechnology company that primarily focuses on developing antibiotics to overcome antibacterial resistance. Its SASPject platform delivers anti-bacterial proteins, such as small acid-soluble spore proteins to selected bacterial species using targetable non-delivery vehicles. The company’s portfolio includes SASPject PT3, an antibiotic against Pseudomonas aeruginosa; SASPject PT4 and SASPject PT5 for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2 that targets Staphylococcus aureus. Phico Therapeutics Limited was incorporated in 2000 and is based in Bourn, United Kingdom.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Emergex Vaccines Holding Ltd is a biotechnology company engaged in the research and development of vaccines for viral and bacterial infectious diseases. Founded in 2016 and based in Abingdon, United Kingdom, Emergex focuses on creating affordable and effective vaccines tailored for low-resource environments that are significantly impacted by pandemics. The company’s vaccine technology targets diseases such as dengue, influenza, zika, hepatitis B, and francisella tularensis. Emergex aims to establish a clinical-grade international vaccine repository that will serve as a first line of defense against both existing and newly emerging infectious disease outbreaks.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Cobra Biologics Limited specializes in contract manufacturing services for biologics and pharmaceuticals, catering to pre-clinical, clinical, and commercial supply needs. The company offers a comprehensive range of services, including cell line development, GMP cell banking, stability testing, protein characterization, and various analytical services. It focuses on producing mammalian and microbial proteins, along with cGMP virus services essential for gene therapy and vaccine production. Cobra Biologics also provides plasmid DNA services, encompassing both non-GMP and GMP processes, and has expertise in aseptic pharmaceutical manufacturing, freeze-drying, and injectable product filling. With facilities in Keele, United Kingdom, and Södertälje, Sweden, the company has built a strong reputation in the global life sciences sector, supporting the development and commercialization of drugs through a combination of integrated and stand-alone services. Founded in 1992 and formerly known as RecipharmCobra Biologics Limited, Cobra Biologics operates as a subsidiary of Cognate BioServices, Inc.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Spoonful of sugar Ltd. provides evidence-based adherence solutions to healthcare providers. Spoonful of Sugar (SoS) are medicines-related behaviour consultants and solution providers. SoS delivers intelligent medicines engagement programmes and evidence-based adherence solutions on behalf of the pharmaceutical industry and healthcare providers. Our programmes are designed to optimise access and adherence to medication as well as increasing stakeholder concordance and improving health outcomes.
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.
Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, focused on DNA therapies and technology. Founded in 2008, the company has developed the proTL synthetic DNA platform, which enables the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach serves various applications including veterinary vaccines, monoclonal antibodies, gene therapy, allergy treatment, RNA interference therapies, and stem cell reprogramming. Touchlight has assembled a skilled team of scientists and drug development experts, led by founder and CEO Jonny Ohlson, who is supported by a dynamic management team. The company has formed strategic collaborations with prestigious academic institutions such as Imperial College London and the University of Pennsylvania, contributing to the advancement of its technologies and the establishment of therapeutic proof-of-principle.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Tusk Therapeutics Ltd develops therapeutic antibodies for the treatment of cancer. The company develops immuno-oncology drugs that work for the depletion of regulatory T-cells (Tregs). The company's products include CD25, a Treg depleting agent and CD38, an immune checkpoint which inhibits immunosuppressive cells. The company was founded in 2014 and is based in Stevenage, United Kingdom. As of September 28, 2018, Tusk Therapeutics Ltd operates as a subsidiary of F. Hoffmann-La Roche Ltd.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Xerion Healthcare Limited is a UK-based company focused on developing and commercializing nanoparticle treatments to enhance the effectiveness of cancer therapies, specifically targeting head, neck, and pancreatic tumors. Founded in 2015, the company utilizes titanium dioxide nanoparticles, a non-toxic semiconductor material, which are injected into tumors prior to standard radiotherapy. This innovative approach amplifies the dose of free radicals produced by X-rays, thereby improving the treatment's efficacy while minimizing potential side effects. By integrating this nanomedicine technology into conventional radiotherapy, Xerion Healthcare aims to provide more effective solutions for patients with challenging cancer types.
CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.
Jellagen Pty Ltd, founded in 2013 and based in Pembroke Dock, United Kingdom, specializes in harvesting jellyfish to produce high-grade native collagen. This innovative Med-Tech company focuses on providing non-mammalian jellyfish collagen, which is essential for various applications in tissue engineering, regenerative medicine, stem cell research, and cell culture. Jellagen's products are designed to meet the needs of medicinal researchers by offering batch-to-batch consistency and versatility for both in-vitro and in-vivo applications. The company's collagen is available in solution or powder form, supporting in-house research and the development of new medical devices aimed at improving wound management and advancing tissue engineering techniques.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.
Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need .
N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
Pertinax Pharma Limited specializes in developing sustained release technology for chlorhexidine, a widely used antiseptic. Founded in 2015 and based in Bristol, United Kingdom, the company focuses on creating controlled release antimicrobial materials applicable in various sectors, including medical, dental, and veterinary fields. Pertinax Pharma's products can be integrated into a diverse range of materials, such as composite fillers, liquids, creams, emulsions, and coatings for metals, polymers, and glasses. By enhancing medical devices and other applications with prolonged antimicrobial and antifungal properties, Pertinax Pharma aims to improve health outcomes and product performance across multiple industries.
Sarissa Biomedical, Ltd. specializes in the development and production of advanced biosensors aimed at measuring neuroactive chemicals in both in vitro and in vivo environments for research and clinical diagnostics. Founded in 2002 and based in Coventry, United Kingdom, the company offers a range of minimally invasive microelectrode electrochemical sensors that provide high sensitivity and accuracy for detecting purines and other neurochemicals. These sensors serve as important indicators of neurological activity and disorders. Sarissa Biomedical markets its products in various regions, including the United Kingdom, the United States, Canada, and Japan, contributing to advancements in the understanding and diagnosis of neurological conditions.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Tecrea Ltd is involved in basic research that results in transformative technologies for biomedicine. We focus on creative ways to use nanotechnology to improve cell delivery of reagents and drugs. We view cell delivery as a central problem in biological research and biomedicine, and improved delivery strategies can enable better application of many reagents and drugs. By improving delivery, Tecrea Ltd enables scientists to bring forward modern molecular medicines to the clinic.
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.